Teleflex Incorporated logo

Teleflex Incorporated(TFX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 14 days
PROFIT SINCE LAST BUY
+11.58% ▲
LAST CLOSE
$155.1
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for TFX

11/13/2026: TFX (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Teleflex Incorporated is a specialized medical device company that has successfully transformed into a focused player in critical care and surgical technologies. Its primary strength lies in its high-margin, recurring-revenue products, such as the UroLift system for urological care and vascular access devices. The investment story centers on organic growth combined with targeted bolt-on acquisitions to expand its footprint in niche markets. Risks include intense competition from larger medical device peers, reliance on hospital budgets, and integration challenges from M&A. The stock may best suit growth-oriented investors interested in the med-tech sector, provided they monitor ongoing reimbursement trends and competitive R&D developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers moderate growth potential linked to specialized medical device adoption rather than explosive industry expansion.
Momentum investorMixed fitStock performance is often tied to clinical trial results and regulatory news flow.
Value investorMixed fitValuation is often premium due to the nature of the med-tech sector.
Dividend investorMixed fitProvides a modest dividend, though not primarily a yield-focused play.
Low-risk investorStrong fit while signal remains positiveOperates in the essential medical device space, which historically provides stable long-term demand.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumMarket sentiment regarding med-tech often fluctuates with sector-wide news and regulatory updates.
Valuation riskMediumInvestors should be cautious of paying high multiples during periods of slowed organic growth.
Competition risk (Market share/innovation)Medium / highConstant pressure from larger rivals like BDX and BSX forces continuous R&D spend.
Business qualityStrongThe company has a strong portfolio of recurring-revenue medical disposables.
Dividend incomeLowNot intended for high-yield income seeking.
Execution riskMediumSuccessful integration of serial acquisitions remains critical to long-term value creation.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.15B USD
Price to earnings Ratio 76.4
1Y Target Price 168.09
Price to earnings Ratio 76.4
1Y Target Price 168.09
Volume (30-day avg) 788.2K shares
Beta 0.83
52 Weeks Range 99.39 - 156.75
Updated Date 11/14/2026
52 Weeks Range 99.39 - 156.75
Updated Date 11/14/2026
Dividends yield (FY) 0.89%
Basic EPS (TTM) 2.03

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -32.42%
Avg. Invested days 34
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
TFX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
TFX has moderate overall fundamentals (3 stars), with moderate financial health, weak growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 12.3%) is partially offset by negative earnings growth (-1399.8%), negative revenue growth (-34.6%), weak profitability (net margin -45.4%).

Financial Health Rating

★★★★★
TFX's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 16.9%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
TFX's growth profile is soft, with the least-weak measure being revenue growth at -34.6% FY2025 versus FY2024. By comparison, while earnings growth (-1399.8%, negative) and free-cash-flow growth (-51.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 124.4% and approximately 99.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.67%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 12.82%
Jupiter Topco LLC 10.25%
T. Rowe Price Investment Management,Inc. 7.54%
Vanguard Portfolio Management, LLC 5.70%
Vanguard Capital Management, LLC 4.71%

Unit Economics (Per $1K Revenue)

★★★★★
TFX generates approximately $562 of gross profit, $128 of operating income, and $123 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and weak cash conversion support a 3-star rating, while capital efficiency is moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: -138.38% (Tax Credit)

Quantitative Style Profile

★★★★★
TFX has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Vascular and Interventional AccessCatheters, EZ-IO systems, and specialized access devices.The bedrock of the company, providing steady, recurring revenue from hospitals.
SurgicalLigation tools and access ports.High-margin specialty tools used in common surgeries.
Interventional UrologyUroLift System.A key growth engine focused on minimally invasive alternatives to traditional surgery.
GeographyGlobal distribution with significant revenue from US and European markets.Well-diversified across developed markets, reducing local economic dependency.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When Before Market
Estimate 1.92
Actual 2.63

Profitability

Profit Margin 13.51%
Operating Margin (TTM) 11.68%

Management Effectiveness

Return on Assets (TTM) 2.32%
Return on Equity (TTM) 2.4%

Valuation

Trailing PE 76.4
Forward PE 13.4
Enterprise Value 7.32B
Price to Sales(TTM) 2.73
Enterprise Value 7.32B
Price to Sales(TTM) 2.73
Enterprise Value to Revenue 3.25
Enterprise Value to EBITDA 17.28
Shares Outstanding 39.66M
Shares Floating 39.50M
Shares Outstanding 39.66M
Shares Floating 39.50M
Percent Insiders 0.67
Percent Institutions 124.42

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.